Deutsche Bank today maintained a Buy rating on Valeant Pharmaceuticals (NYSE: VRX) and raised its price target to $83.00 (from ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE